CITI on Cipla
Buy, TP Rs 1700
Cipla’s Pithampur facility received seven observations following a USFDA cGMP inspection conducted during 17–25 August 2026
Expect no impact on near- to medium-term earnings, as key pipeline approvals are linked to the Goa and US facilities
While details of observations are awaited, even a further delay in regulatory resolution is unlikely to affect earnings estimates, as Pithampur is already under a Warning Letter
However, resolution would be a significant positive over longer term, enabling Cipla to manage supplies of key respiratory products, including gSymbicort and gVentolin, more efficiently.
August 26, 2026 52
